Stemline Therapeutics
Pre-clinicalELZONRIS (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $70M
About
ELZONRIS (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Cell & Gene Therapy
Funding History
3Total raised:$70M
IPO$40MMar 21, 2013
Series B$20MJun 15, 2007
Series A$10MJun 15, 2004